Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

David S. Miller, Virginia L. Filiaci, Robert S. Mannel, +15

Journal of Clinical Oncology

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy, +7

Journal of Clinical Oncology

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Maurie Markman, John A. Blessing, Stephen C. Rubin, +3

Gynecologic Oncology

Phase Ii TrialMedicineCancer ManagementGynecologyWeekly Paclitaxel +6

Adverse psychologic consequences of positive cYtologic cervical screening

Caryn Lerman, Suzanne M. Miller, Ruth Scarborough, +3

American Journal of Obstetrics and Gynecology

Cervical Cancer ManagementCervical Cancer ScreeningCervical CancerCervical HealthAdverse Psychologic Consequences +9

Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

David S. Miller, John A. Blessing, Carolyn Krasner, +5

Journal of Clinical Oncology

Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

Matthew A. Powell, Virginia L. Filiaci, Peter G. Rose, +6

Journal of Clinical Oncology

Topotecan in Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group

Michael A. Bookman, John A. Blessing, Parviz Hanjani, +2

Gynecologic Oncology

Tumoral PathologyCervical CancerSquamous Cell CarcinomaMedicineGynecology +11

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study

Gini F. Fleming, Virginia L. Filiaci, Brandon Marzullo, +12

Gynecologic Oncology

Megestrol AcetateMedicineGynecologyEndometrial CancerOncology +5

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

Kimberly K. Leslie, Michael W. Sill, Heather A. Lankes, +9

Gynecologic Oncology

MedicineGynecologyCancer GenomicsRecurrent Endometrial CancerPotential Prognostic Value +4

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer

Debra L. Richardson, Michael W. Sill, Robert L. Coleman, +13

JAMA Oncology